PTGX - Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. , a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications.
As of May 15, 2026: spot at $102.63, ATM IV 39.1%, max pain $90.00, net GEX $49.4K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $6.68B
- Beta
- 1.88
- 52-Week Range
- 43.465-107.84
- CEO
- Dinesh V. Patel
- Employees
- 124
- IPO Date
- Aug 11, 2016
- Exchange
- NASDAQ
What PTGX Looks Like to Options Traders Today
IV rank of 3.7% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($49.4K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.047) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The PTGX overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked PTGX overview questions
- What is PTGX?
- PTGX is the ticker symbol for Protagonist Therapeutics, Inc., a listed security. Protagonist Therapeutics, Inc. , a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. Listed on NASDAQ. PTGX is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the PTGX options snapshot look like today?
- As of May 15, 2026, the PTGX options snapshot shows spot at $102.63, ATM IV 39.1%, IV rank 3.7%, max pain $90.00, net GEX $49.4K, expected move 11.21%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are PTGX's key statistics?
- Protagonist Therapeutics, Inc. (PTGX) carries a market capitalization of $6.68B, beta of 1.88 relative to the broader market, 52-week range of 43.465-107.84. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does PTGX belong to?
- Protagonist Therapeutics, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare PTGX's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the PTGX data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).